AISC616.0

Translational Biomedical Engineering

Credits: 4 CREDITS (2P+2B)
Sites: HMS and Clinical Sites
Director(s): Ryan Carroll, David Walt
Offered: February
Location: HMS - Harvard Medical School (0)
Open to Exclerks: No (HMS only)
Description: Summary: Innovations in biomedical engineering are having a significant impact on healthcare. Advances in genomics technologies are transforming diagnostics/therapeutics, including personalized medicine. Prosthetic technologies are giving patients who have lost a limb the opportunity to lead near-normal lives. Robots, swallowed or injected, are changing surgery and diagnostics. Nanomaterials are being used as therapeutics and for new imaging modalities. The course is designed to provide students with an understanding of the entire process from academic discovery to commercial and patient impact with a focus on medical devices and biomedical engineering. Students will interact with faculty who have successfully translated their work to the private sector and will spend time in labs at the Wyss Institute where novel technologies are currently being developed. Students will also meet with investors, visit startup companies to see how technologies are scaled and manufactured, and meet with business development and marketing groups. Student teams will then be tasked with going into the clinic and developing a novel clinical use for a specific technology. Format of classroom-based sessions: This course will deploy lectures from leaders in the field including researchers, venture capitalists, business development experts, corporate leaders and clinical trials experts. Students will engage with the primary literature in which the initial technology was reported. As a final project, students working in teams will develop a business model for a new technology informed by clinical need. Format of clinical/field experiences: The course will incorporate a variety of experiences illustrating the translational spectrum all the way from initial discovery to clinical implementation. During lab immersions, students will interact directly with researchers developing new technologies. They will also interact with venture capitalists, and visit companies to interact with engineers, business development experts, and corporate leaders who are converting new technologies into manufacturable commercial products that meet a market need. For companies that are carrying out clinical trials, students will meet with clinical trials experts. Students will engage with multiple technologies during the course so they can experience different approaches to successful commercialization. Anticipated schedule: All AISCs are full time courses. Students are expected to devote at least 40 hours per week to scheduled sessions and preparatory work. This course will hold daily afternoon four-hour sessions during weeks 1, 2 and 4 that include classroom time and lab immersion, as well as daily biotech industry visits during week 3.